{"id":4010,"date":"2026-10-30T09:00:00","date_gmt":"2026-10-30T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=4010"},"modified":"2026-10-31T12:00:45","modified_gmt":"2026-10-31T16:00:45","slug":"setara-closes-90-million-dollar-series-a","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=4010","title":{"rendered":"Setara Closes 90 Million Dollar Series A"},"content":{"rendered":"

\"\"<\/p>\n

Company<\/strong><\/p>\n

Setara Biosciences; Jazz Pharmaceuticals (Actio asset)<\/p>\n

Event Type<\/strong><\/p>\n

Series A financing<\/p>\n

Modality<\/strong><\/p>\n

Oral small-molecule TRPV4 inhibitor<\/p>\n

Asset<\/strong><\/p>\n

STAR-0871 (formerly ABS-0871)<\/p>\n

Target<\/strong><\/p>\n

TRPV4<\/p>\n

Disease Area<\/strong><\/p>\n

Charcot-Marie-Tooth type 2C; overactive bladder<\/p>\n

Summary<\/h4>\n

Setara Biosciences announced on 30 October that it completed a $90 million Series A after Jazz acquired Actio\u2019s lead KCNT1 epilepsy asset. Setara retains the remaining genetics-led pipeline, led by the TRPV4 inhibitor STAR-0871. This is a closed new-capital round, not a recycled announcement of the Actio sale.<\/p>\n

Participating investors include Deerfield, Canaan, Droia Ventures, EcoR1, Euclidean Capital, Regeneron Ventures and Jazz. The release does not designate a lead investor or disclose runway. STAR-0871, formerly ABS-0871, completed a healthy-volunteer Phase I portion; Setara plans Phase Ib CMT2C and Phase IIa overactive-bladder studies. These trial starts are guidance, not completed readouts. The company identifies David Goldstein as president and executive chair, with several former Actio leaders transferring. The new entity and financing are the primary signal; leadership is described as context rather than a separate succession event.<\/p>\n

Deep Analysis<\/h4>\n

Gain-of-function TRPV4 variants give CMT2C a unusually clear genetic target, while overactive bladder is a broader biological extension that requires independent validation. A single small molecule across both indications could create development efficiency, but the bladder mechanism, therapeutic index, systemic exposure and relevant tissue penetration remain unproven. Human healthy-volunteer exposure does not establish disease efficacy. The capital and experienced syndicate support simultaneous rare-disease and expansion trials, but no cash runway or allocation was disclosed. IP continuity from Actio and Jazz\u2019s retained relationship merit attention, yet the precise rights and manufacturing obligations are not public.<\/p>\n

Company and Product Background<\/h4>\n

CMT2C is a rare hereditary motor and sensory neuropathy caused by activating TRPV4 variants. STAR-0871 is an oral TRPV4 channel inhibitor intended to counter pathogenic overactivity; the proposed overactive-bladder indication is a separate clinical question.<\/p>\n

Signal Extraction<\/h4>\n
    \n
  • Interpretation A:<\/strong> investors funded a coherent rare-to-common precision-medicine strategy, supported by genetics, an existing clinical candidate and a completed round.<\/li>\n
  • Interpretation B:<\/strong> the transaction reorganizes assets whose larger-indication thesis remains uncertain.<\/li>\n
  • Upgrade<\/strong> with biomarker-linked CMT2C improvement, bladder efficacy against credible controls and tolerable chronic exposure. Downgrade<\/strong> with TRPV4-mediated safety limitations or no symptom benefit despite target engagement. Failure of both disease-context trials would falsify<\/strong> platform leverage.<\/li>\n<\/ul>\n

    InSilens Take<\/h4>\n

    Inference: the round gives a newly formed clinical-stage company capacity to test TRPV4 in two distinct markets. Financing is validated; therapeutic breadth is a hypothesis.<\/p>\n

    Signal Assessment<\/h4>\n

    Signal Importance: 4 of 5. Signal Direction: positive for capital, uncertain for asset value. Confidence in Facts: high for financing and disclosed stage. Confidence in Interpretation: moderate to low.<\/p>\n","protected":false},"excerpt":{"rendered":"

    Setara Biosciences announced on 30 October that it completed a $90 million Series A after Jazz acquired Actio\u2019s lead KCNT1 epilepsy asset. Setara retains the remaining genetics-led pipeline, led by the TRPV4 inhibitor STAR-0871….<\/p>\n","protected":false},"author":1,"featured_media":4012,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[1323,879,1320,1321,1322],"class_list":["post-4010","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-deals-and-financing","tag-jazz-pharmaceuticals","tag-series-a","tag-setara-biosciences","tag-star-0871","tag-trpv4"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4010","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4010"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4010\/revisions"}],"predecessor-version":[{"id":4029,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4010\/revisions\/4029"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/4012"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4010"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4010"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4010"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}